Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Gilead’s oral JAK inhibitor filgotinib wins EU approval

pharmatimesSeptember 30, 2020

Tag: gilead , JAK inhibitor , filgotinib , Rheumatoid Arthritis , Jyseleca

PharmaSources Customer Service